Retinal toxicities of systemic anticancer drugs |
| |
| Institution: | 1. Bahamas Vision Center and Princess Margaret Hospital, Nassau, New Providence, Bahamas;2. Jamaica Hospital Medical Center, New York Medical College, Jamaica, New York, USA;3. Eye Care Centre, Princess Margaret Hospital, Nassau, New Providence, Bahamas;4. Department of Ophthalmology, UPMC Eye Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA;5. Uveitis and Ocular Immunology Services, L V Prasad Eye Institute, Hyderabad, India;6. Department of Biochemical and Surgical Sciences, Section of ophthalmology, University of Perugia, Perugia, Italy;7. UPMC Eye Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA;1. Glaucoma Service, Instituto de Olhos Ciências Médicas, Belo Horizonte, Brazil;2. Ophthalmology Department, Federal University of São Paulo, São Paulo, Brazil;3. Einhorn Clinical Research Center, New York Eye & Ear Infirmary of Mount Sinai, New York, NY, USA;4. Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA;1. Retina and Vitreous Department at Asociación Para Evitar la Ceguera (APEC), CDMX, México, I.A.P.;2. Latin American Network for Research in Eye Diseases-LANRED;3. Research Unit, Clínica Vista, Lima, Peru;4. Buenos Aires Mácula, Buenos Aires, Argentina;5. Hospital Universitario Austral, Pilar, Buenos Aires, Argentina |
| |
| Abstract: | Newer anticancer drugs have revolutionized cancer treatment in the last decade, but conventional chemotherapy still occupies a central position in many cancers, with combination therapy and newer methods of delivery increasing their efficacy while minimizing toxicities. We discuss the retinal toxicities of anticancer drugs with an emphasis on the mechanism of toxicity. Uveitis is seen with the use of v-raf murine sarcoma viral oncogene homolog B editing anticancer inhibitors as well as immunotherapy. Most of the cases are mild with only anterior uveitis, but severe cases of posterior uveitis, panuveitis, and Vogt-Koyanagi-Harada-like disease may also occur. In the retina, a transient neurosensory detachment is observed in almost all patients on mitogen-activated protein kinase kinase (MEK) inhibitors. Microvasculopathy is often seen with interferon α, but vascular occlusion is a more serious toxicity caused by interferon α and MEK inhibitors. Crystalline retinopathy with or without macular edema may occur with tamoxifen; however, even asymptomatic patients may develop cavitatory spaces seen on optical coherence tomography. A unique macular edema with angiographic silence is characteristic of taxanes. Delayed dark adaptation has been observed with fenretinide. Interestingly, this drug is finding potential application in Stargardt disease and age-related macular degeneration. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
